A patient at 14 weeks pregnancy, on her routine antenatal panel, tests positive for HBsAg. Which of the following is true about her condition?
First, I need to recall the core concepts. HBsAg is a surface antigen indicating HBV infection. In pregnancy, it's crucial because of the risk of mother-to-child transmission. The main concern here is preventing perinatal transmission.
The correct answer would likely relate to management or implications of HBV during pregnancy. Let's think about the options. The options aren't provided, but based on common questions, possible answers might include the need for antiviral therapy, timing of delivery, or postnatal prophylaxis.
HBV can be transmitted to the baby during childbirth. The risk is highest if the mother has high viral load. Antiviral therapy, like tenofovir, might be recommended in the third trimester to reduce viral load. Postnatal prophylaxis with HBIG and vaccine is standard.
Now, incorrect options might suggest unnecessary treatments, wrong timing of interventions, or incorrect transmission rates. For example, stating that all HBsAg positive mothers transmit the virus at birth is wrong because the actual rate is around 10-20%, but drops to less than 5% with proper prophylaxis.
Clinical pearls: All pregnant women should be screened for HBsAg. Antiviral therapy in third trimester for high viral load to reduce perinatal transmission. Newborns need HBIG and vaccine within 12 hours.
**Core Concept:** Hepatitis B surface antigen (HBsAg) positivity in pregnancy indicates chronic HBV infection, which carries a significant risk of perinatal transmission. Management focuses on reducing viral load and implementing postnatal prophylaxis to prevent infant infection.
**Why the Correct Answer is Right:** A positive HBsAg test confirms HBV infection. Perinatal transmission occurs in 10–20% of untreated cases but drops to <5% with antenatal viral load monitoring, tenofovir use in high-load cases (third trimester), and postnatal administration of hepatitis B immune globulin (HBIG) plus vaccine within 12 hours of birth. This answer aligns with evidence-based guidelines for HBV management during pregnancy. **Why Each Wrong Option is Incorrect:** **Option A:** Suggesting that antiviral therapy is unnecessary ignores the role of tenofovir in reducing viral load and transmission risk. **Option B:** Claiming that transmission occurs only if HBeAg is positive is incorrect; HBsAg alone identifies infectivity. **Option C:** Delaying newborn prophylaxis beyond 12 hours reduces its efficacy, contradicting CDC recommendations. **Clinical Pearl / High-Yield Fact:** All pregnant women must be screened for HBsAg early in pregnancy. For HBV-positive mothers with ≥200,000 IU/mL viral load, tenofovir at 28–32 weeks is recommended. **Postnatal prophylaxis is non-negotiable**—HBIG + vaccine within 12 hours prevents 90% of transmissions. **Correct Answer: C. Antenatal antiviral therapy and postnatal HBIG + vaccine prevent perinatal transmission**